The Current and Future Therapies for Human Osteosarcoma

Author(s): Joseph D. Lamplot, Sahitya Denduluri, Jiaqiang Qin, Ruidong Li, Xing Liu, Hongyu Zhang, Xiang Chen, Ning Wang, Abdullah Pratt, Wei Shui, Xiaoji Luo, Guoxin Nan, Zhong-Liang Deng, Jinyong Luo, Rex C Haydon, Tong-Chuan He, Hue H. Luu

Journal Name: Current Cancer Therapy Reviews

Volume 9 , Issue 1 , 2013

Become EABM
Become Reviewer


Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults and children. As sarcomas are more common in adolescents and young adults than most other forms of cancer, there are a significant number of years of life lost secondary to these malignancies. OS is associated with a poor prognosis secondary to a high grade at presentation, resistance to chemotherapy and a propensity to metastasize to the lungs. Current OS management involves both chemotherapy and surgery. The incorporation of cytotoxic chemotherapy into therapeutic regimens escalated cure rates from <20% to current levels of 65-75%. Furthermore, limb-salvage surgery is now offered to the majority of OS patients. Despite advances in chemotherapy and surgical techniques over the past three decades, there has been stagnation in patient survival outcome improvement, especially in patients with metastatic OS. Thus, there is a critical need to identify novel and directed therapy for OS. Several Phase I trials for sarcoma therapies currently ongoing or recently completed have shown objective responses in OS. Novel drug delivery mechanisms are currently under phase II and III clinical trials. Furthermore, there is an abundance of preclinical research which holds great promise in the development of future OSdirected therapeutics. Our continuously improving knowledge of the molecular and cell-signaling pathways involved in OS will translate into more effective therapies for OS and ultimately improved patient survival. The present review will provide an overview of current therapies, ongoing clinical trials and therapeutic targets under investigation for OS.

Keywords: Bisphosphonates, BMP, IGF, IGFBP5, limb-salvage, osteosarcoma, OS99.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 04 February, 2013
Page: [55 - 77]
Pages: 23
DOI: 10.2174/1573394711309010006

Article Metrics

PDF: 64